This cluster groups 2 independently calculated changes: Cash & equivalents decreased 35.7%; Operating cash flow decreased 16.7%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTSilexion Therapeutics Corp's latest supported as-filed period reports interest income of $14,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 35.7%; Operating cash flow decreased 16.7%.
2 evidence-backed componentsShares outstanding changed +660.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
SLXN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001178913-26-004849SEC ↗8-KSep 30, 2026Period Sep 30, 20260001178913-26-004666SEC ↗8-KSep 29, 2026Period Sep 28, 20260001178913-26-004645SEC ↗8-KSep 28, 2026Period Sep 28, 20260001178913-26-004628SEC ↗8-KSep 25, 2026Period Sep 25, 20260001178913-26-004609SEC ↗8-KSep 25, 2026Period Sep 25, 20260001178913-26-004604SEC ↗8-KAug 21, 2026Period Aug 21, 20260001178913-26-004223SEC ↗10-QTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2026Filed Jun 8, 2026 | Shirvan MitchellCSO and CDO | Grant Or AwardDirect | 6,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -61.1% from the comparable as-filed period.
Research & development changed +117.3% from the comparable as-filed period.
Net income changed -41.9% from the comparable as-filed period.
Free-cash-flow proxy changed -16.6% from the comparable as-filed period.
Operating cash flow changed -16.7% from the comparable as-filed period.
Cash & equivalents changed -35.7% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001178913-26-004138